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Characterization of peritoneal macrophages taken from patients on
peritoneal dialysis. A.F. Serre, A. Tridon, C. Rapatel, J. Bonhomme, and P.
DeteL CHU Cler,nont-Ferrand, Clermont-Ferrand, France. To finalize
biocompatibility tests, we studied during several months macrophages
from freshly drained dialysate of 4 patients on CAPD without peritonitis
(clinical examination, bacteriology and limulus test). The cells of the
peritoneal effluents were concentrated by centrifugation prior to isolation
of the mononuclear cells on Ficoll 1.077. Viability was asserted by Trypan
blue exclusion. Purity was estimated on cytocentrifuged preparations after
stainings with May-Grunwald-Giemsa and nonspecific esterase. The cell
respiratory burst was explored by chemiluminescence performed with a
luminol enhanced system before and after stimulation by phorbol my-
ristate acetate PMA (1.5 nM) and formyl methionyl leucyl phenylalanine
fMLP (0.2 mM). Flow cytometry of isolated mononuclear cells (1 patient)
was performed with the use of a flow cytometer (cytoron Ortho) and
monoclonal antibodies CD14 and CD25 (Dako). The number of cells in
the effluent ranged from 10 to 100/pi with a mean of 20% neutrophils,
15% eosinophils, 15% lymphocytes, and 50% macrophages. One patient
had peritoneal hypereosinophilia. After isolation, the number of mono-
nuclear cells ranged from 2 to 12 106. Viability was superior to 95% and
macrophage purity was more than 70%. Expression of CD14 was about
40% and of CD25 inferior to 3%. Before activation, chemiluminescence
was for each patient 2.1 1.7; 14.3 21.5; 5.3 1.8; and 8.4 7.3
millivolts for 106 cells. After stimulation by PMA, chemiluminescence
values were 52.7 23.2; 252.2 113.6; 153.9 51.9; and 110.6 56.2.
Response latent time was inferior to 1 minute, and the peak was between
2 and 3 minutes. There was a correlation between chemiluminescence
values before and after activation in 3 patients (Spearman test). After
stimulation by fMLP, there was no latent time and the peak was obtained
in 45 seconds. In three patients tested chemiluminescence values were
138.6 87.8; 48.8 22.5; and 50 15.3. Peritoneal macrophages produce
chemiluminescence with variability in the amplitude of the signal. High
chemiluminescence before and after activation suggests cell priming in
vivo. Peritoneal macrophages keep activation capacities and seem to be an
appropriate tool for use in biocompatibility studies.
Antiphospholipid (APL) antibodies in hemodialysis patients. P. Brunet,
M.F. Aillaud, M San Marco, B. Dussol, I. Juhan-I/ague, D. Bernard, and Y.
Berland, Nephrology Department, Sainte-Mauerite Hospital, and Hematol-
ogy and Immunology Laboratories, La Timone Hospital, Marseille, France.
We previously reported the significant relationship between lupus antico-
agulant (LA) and history of vascular access thrombosis in a population of
dialysis patients. We present here the study of the two most common
antibodies: LA and anticardiolipin (ACA). LA was assessed by 3 different
methods: APTI', PTT-LA and TTI; ACA was measured by ELISA IgG.
We studied 97 patients. Those with lupus or treated with drugs which can
induce APL were excluded. Total APL prevalence was 31% (N = 30). LA
was found in 16.5% (N = 16); ACA was found in 15.5% (N = 15). There
was no relation between APL and age, sex, time on dialysis, type of
membrane, initial ncphropathy or chronic B and C hepatitis. The influ-
ence of APL on thrombosis was retrospectively analyzed. There was only
1 significant relationship, between LA and history of vascular access
thrombosis (62% in LA positive vs. 26% in LA negative patients, P = 0.01,
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odd ratio 4.76). ACA was not associated with vascular access thrombosis.
It could be associated with arterial thrombosis but the relationship was not
significant (P = 0.13). In conclusion, only lupus anticoagulant seems to be
relevant in dialysis patients, because it is associated with vascular access
thrombosis.
Evidence for a specific alteration of glycoprotein sialylation induced by
cyclosporine. R. Cahen, P. Broquet, M. Richard, P. Louiso4 and A. Martin,
Service de Néphrologie, Centre Hospitalier Lyon-Sud, Pierre Bénite, and
INSERM-CNRS U189, Faculté de Médecine Lyon-Sud, Oullins, France.
Cyclosporine (C5A) is known to impair cytosolic calcium signaling. The
CsA-cyclophilin complex inhibits the phosphatase enzymatic activity of
calcineurin, thus impairing protein phosphorylation. Moreover, sialyl-
transferase phosphorylation modulates the fixation of sialic acid on
glycoconjugates and is related to a calcium-dependent protein kinase.
These facts prompted us to look for an effect of CsA on the enzymatic
glycosylation processes using 2 different approaches, in vivo in rats and in
Vitro m cultured cells. Adult male Sprague Dawley rats were distributed in
3 groups of 4 animals and injected subcutaneously for 30 days with CsA
(20 mg/kg/day) or cremophor or normal saline. After harvesting and
homogenization of the kidneys, proteins were separated by polyacrylamide
gel electrophoresis, then transferred to a nitrocellulose membrane and
revealed by enzyme-labeled lectins, specific for different sugars (sialic acid,
fucose, galactose, mannose). Gangliosides were extracted and analyzed by
thin layer chromatography. In vivo, CsA was tested with C6 cultured cells,
derived from a rat glioblastoma and on which sialylation regulation by
phosphorylation has been shown. Among all the lectins tested, only
Sambucus nigra agglutinin, specific for a(2-6)-bound sialic acid, demon-
strated an impairment in sialylation of a 200 kD glycoprotein in the
CsA-treated rats as compared to control animals (cremophor or normal
saline). On the contrary, CsA did not modify renal gangliosides. In C6
cultured cells, CsA impaired sialylation of a 220 kD glycoprotein and
inhibited a(2-3) sialyltransferase activity in a dose-dependent way. In
conclusion, CsA has a specific effect on sialylation of glycoproteins but not
of glycolipids. Considering the known biological roles of glycoprotein
sugars, this effect may contribute to the mechanisms of cellular injury in
CsA chronic nephrotoxicity.
Ultraviolet irradiation (UVI) in disinfection of water for hemodialysis.
7'. Cao-Huu, P. DiMajo, L. Frimat, D. Hestin, M.F. Blech, P.H. Hartemann,
and M. Kessler, Departments of Nephrology and Hygiene, .H. U, Nancy,
France. UVI has recently been used in water treatment for hemodialysis as
an alternative to chlorine. The authors assayed the Berson UV Generator
(FSI-U2VL1B1) using this process. In the first phase, the UV tube was set
in in vitro equipment with a 625 liter tank, 32 mm section tube, and single
pass water flow rate at 1500 L/H. The tank was fed with water which
circulated through a ten year old activated charcoal filter. Five 25 minute
single pass assays were performed during the first week. Then water after
the UV tube was sent back to the tank for three 24 hour recirculations,
separated by 24 hours. In the in vivo phase, the UV tube was set in the
water treatment installation of 2 dialysis units and downstream of the
activated charcoal filter. Samples were drawn: before and after the UV
tube, during single pass phase, every 5 minutes for bacterial Counts (Bact)
and at tO and t25 minutes for endotoxin Pyrotell Limulus Test (Endo);
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during the recirculation phase, at tO, t2H and t24H for Bact; and during
the in vivo phase, twice per week for Bact and Endo. Results:
Before UV After UV (%)
Endotoxin UI/mi
Single pass Bact
cfu/mI
Recirculation Bact
cfu/ml
In vivo Bact
cfu/ml
(11)
(30)
(9)
(10)
6.5 7.3
8.1 X io
28 x 106
4.1 X iO
6 >< iO
2.8 X iO
2.7 x iO
6.2 7.8
1.4 X 102
5.6 >< 10230 6
10 12
99.9 17
90.9 17
99.5 0.5
Conclusions: Our study showed high bactericid activity of UVI used in the
disinfection of water for hemodialysis without elevation of the endotoxin
level downstream of the UV. High endotoxin levels in spite of low
bacterial values after UV suggested that the UV tube is to be placed
upstream of the endotoxin filters. A current in vivo study in water
treatment of our dialysis units will teach us more about long-term results
and maintenance.
Single pump-single needle hemodialysis (SP-1NH) compared to double
pump-1NH (DP-1NH) and two needle hemodialysis (2NH). T Cao-Huu,
L. Frimat, D. Hestin, J. Hubert, F. Lebhour, and M Kessler, Departments of
Nephrology and Urology, University of Nancy, Nancy, France. SP-INH is
rarely performed in spite of material improvement. In this study, the
efficiency of SP-1NH was compared to DP-1NH on the one hand, and to
2NH on the other. Eight patients aged 53 15 years, dialyzed for 51 60
months with Hemotech tunnelized single catheters since 5.9 4 months
while waiting for a new vascular access, were treated in 4 sequences: 1
week with SP-INH, 1 week with DP-1NH, 1 week with 2NH and blood
pump at 200 mI/mm, 1 week with 2NH and blood pump at 300 mI/mm. All
1NH treatments were performed with an average blood flow rate (aBFR)
of 200 mI/mm. Each sequence consisted of 3 treatments per week with the
same 5 hour duration and dialyzer (Gambro iE600). Access recirculation,
urea reduction ratio (URR), urea post/pre-dialysis ratio (UR), KT/V =
{ —ln(UR — 0.03) + (4 — 3.5UR) * UF/W} and whole cleared blood
volume/weight index (wcbv/W) were monitored. Results:
SP-1NH
(8 patients)
DP-1NH
(8 patients)
2NH (6p)
200 mI/mm
2NH (Sp)
300 mi/mm
URR% 70±8 71±6 72±7 79±5
UR 0.30 0.08 0.29 0.06 0.28 0.07 0.21 0.05
KT/V 1.58 0.37 1.61 0.38 1.62 0.29 2.00 0.36
wcbv/W 1.07 0.27 1.08 0.24 1.1 0.24 1.71 0.23
Conclusions: Single pump-1NH, DP-1NH, and 2NH in our study had the
same efficiency when they were performed with the same BFR, dialyzer
and duration. The 2NH results were significantly better than 1NH only
when BFR was higher (300 mI/mm), thanks to the new vascular access.
SP-1NH and BFR and wcbv/W index could be more easily understood
than DP-1NH, KT/V and UR by the staff when using SNH.
Primary IgA nephropathy is associated with HLA DQB1*0301 allele
(DQ7). D. Chevet, F. Guignier, V. Tanter, J.M. Rebibou, J.M. Chalopmn, C.
Mousson, P. Chatelain, and G. Rifle, Nephroiogy Transplantation Unit,
Centre Hospitalier Regional et Universitaire du Bocage, and Centre Regional
de Transfusion Sanguine, Dijon, France. An association between primacy
IgA nephropathy (IgAN) and HLA class II has been described. However,
with serologically-defined antigens, conflicting results appeared from
different studies. We investigated the possible correlation between fre-
quency of HLA DRB1 and DQB1 alleles and IgAN. DRB1 genotyping
was performed using polymerase chain reaction (PCR) and hybridization
with sequence-specific olignucleotide probes, and DQB1 genotyping was
carried out using allele specific restriction endonuclease (PCR-RLFP).
Fifty-four biopsy-proven idiopathic IgAN unrelated caucasoid patients
were studied. All were treated in the same hospital for chronic renal
failure (CRF): maintenance therapy (N 13), dialysis (N = 19), renal
transplant (N = 22). Non-primacy IgAN (such as alcoholics, SLE) were
carefully excluded. Two control groups were constituted: the first control
(CRF) included 44 non-primacy IgA chronic renal failure patients
matched for renal failure, dialysis and transplantation; the second control
(normal) was constituted of 105 French caucasoid blood bank donors. This
study indicated that the DQBI *0301 allele was significantly increased in
IgAN patients (59.3%) versus CRF control (31.8%, relative risk = 3.2)
and versus normal controls (29.5%, P = 0.001, rr = 3.6). DRB1 * 11 generic
specificity was also increased in IgAN patients (40.7%) versus CRF
control (22%) and normal control (18%, P = 0.01; rr = 3.1). On the other
hand, 40.7% of DQB1*0301 IgAN patients inherit DRB1*11 generic
versus 20.4% (CRF control) and 15.2% (normal control). These results
imply that DQBI*0301 allele (DQ7) specificity is strongly associated with
CRF primacy IgA nephropathy susceptibility, and that the linkage disequi-
librium between DQBI*0301 and DRB1*11 generic seems more fre-
quently encountered in IgA nephropathy than in controls. These findings
focus on the immunogenetic importance of the DQB region in IgAN.
Thrombotic microangiopathy after renal transplantation: Clinico-
pathological correlation and treatment. J.M. Cisterne, L. Rostaing, A.
Modesto, and D. Durand, Department of Oigan Transplantation, University
of Toulouse III, Toulouse, France. Histopathological findings of thrombotic
microangiopathy lesions are often found on renal transplant biopsies.
They are the expression of endothelial injuries but their mechanisms and
etiologies remain to be defined. Over a 10-year period, 530 renal
transplantations have been performed in our institution. Of all the renal
biopsies performed in these patients for various reasons, histological
lesions of glomerular thrombotic microangiopathy, that is, thrombi,
parietal lesions, mesangiolysis, and leucocyte infiltration, with or without
arteriolar lesions, were observed in 16 cases, in 14 patients (that is, a
frequency of 3%). With regard to clinical and other histological parame-
ters, these 16 cases were classified in 5 groups: (i) vascular rejection (5
cases); (ii) vascular rejection associated with ciclosporine A (CsA) neph-
rotoxicity (2 cases); (iii) CsA nephrotoxicity (3 cases); (iv) recurrence of
thrombotic microangiopathy (3 cases); (v) unclassified (3 cases). Glomer-
ular lesions were associated with arteriolar lesions in 9 cases: the latter was
always observed in vascular rejection. A moderate interstitial mononu-
clear cell infiltration was found in 6 cases, in a context of vascular
rejection. Tubular lesions were observed in 14 Out of 16 cases; they were
not useful for diagnosis. There was no correlation between glomerular
lesions, etiology, and prognosis. Heniolytie uremic syndrome (HUS) was
present in all cases of CsA nephrotoxicity and in 2 out 3 of those with
recurrence. On the contrary, HUS was absent in the context of vascular
rejection. Vascular rejections were treated in 6 out 7 cases with OKT3,
with a good outcome at 1 month (mean serum creatinine 144 30 vs. 254
125 smol/liter; P = 0.02) but poor at 6 months (mean serum creatinine:
258 150 jrmol/liter in 6 patients; the last one returned to dialysis). CsA
nephrotoxicity was treated with success by CsA withdrawal (and plasma
exchanges in 2 cases). Finally, the 3 cases of HUS recurrence had a poor
outcome despite CsA withdrawal and plasma exchanges (with fresh frozen
plasma). The histological finding of thrombotic microangiopathy is quite
rare after renal transplantation; HUS is not always present, especially in
the context of vascular rejection. Etiological diagnosis is often difficult
since many pathological mechanisms are involved; nevertheless, CsA is
often a triggering or enhancing factor. Except for CsA nephrotoxicity,
these lesions are usually pejorative; if rejection is absent, a question
remains: are CsA withdrawal and plasma exchanges useful?
Epidemiology of primary hyperoxaluria type 1. P. Cochat, A. Deloraine,
F. Olive, I. Liponski, M. Rotily, and N. Deries, on behalf of the Société de
Nephrologie and the Société de Nephrologie Pediatrique, Unite de Néphrolo-
gie Pediatrique, Hôpital Edouard Herriot, Lyon; and CAREPS, CHU
Grenoble, OXAL Association, Grenoble, France. Primary hyperoxaluria
type I (PHi), an autosomal recessive inborn error of glyoxylate metabo-
lism, always leads to insoluble oxalate accumulation throughout the body,
called oxalosis. Except when renal replacement therapy (RRT) is re-
quired, no epidemiological data are currently available. French nephrolo-
gists (Société de Nephrologie Registry) were questioned in 1993 about
PHi patients who were referred to them between 1988 and 1992.
Exhaustive answers were obtained either by mail or by phone. Ninety-five
cases (male/female 1.33) of PH were collected: 39 were new patients and
5 were excluded (3 PH2, I PH3, 1 incomplete observation). The average
prevalence was 1.05/106 and the average incidence was 0.12/106 per year.
The median age at clinical onset was 5 years (range 0—63) and initial
symptoms involved the urinary tract in 82% of the cases. Half of the
patients were younger than 10 years at the time of diagnosis (median 10
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years, range 0—65), established by urine oxalate (89%) urine glycolate
(43%) plasma oxalate (71%) hepatic alaninc-glyoxylate aminotrans-
ferasc activity (48%). At the time of the survey, 36% were on conservative
treatment, 37% were transplanted, and 27% were on dialysis. Patients on
dialysis started RRT at a median age of 25 years (21% < 10 years of age).
Transplanted patients received their first transplant at a median age of
29.5 years (13% < 10 years of age); 26 of them were followed for more
than 1 year: 15 isolated kidney transplantations (I success), 1 isolated liver
transplantation (1 success), and 10 combined liver/kidney transplantations
(8 successes). The overall mortality rate was 19% (median age 36 years,
1/3 died before 20 years of age). These data confirm that the rarity of PHi
(5 to 9 new cases per year in France) together with its poor outcome,
makes early liver and/or kidney transplantation necessary.
Increased sensitivity of anti.idiotypic antibody detection by anti-HLA
class I antibody absorption on platelets. C. Jolimoy, A. Ramounau, J.
Seignalet, P. Fabro, G. Mourad, G. Rifle, and J. Clot, Laboratory of
Nephrology-Hemapheresis- Transplantation, University Hospital Dijon; De-
partment of Medical Statistical Analysis, University Hospital l\IImes; and
Laboratory of Immunology and Department of Nephrology, University Hos-
pital, Montpellier, France. Anti-HLA class I antibodies (Abi) detected
before renal transplantation can sometimes spontaneously disappear.
When this happens, the hypothesis is that anti-idiotypic antibodies (Ab2)
neutralize Abi. In this situation, renal grafting can be successful in
patients who previously had Abi directed against HLA antigens of the
kidney graft. Outcome of kidney transplantation is poor when Ab2 are not
found in current sera. However, it seems possible that Abi and Ab2
binding could lead us to consider some sera as Abi negative and also that
Ab2 detection can falsely appear negative. Therefore, in negative lympho-
cytoxicity sera, it could be possible to increase the sensitivity of Ab2
detection by Abi absorption on pooled platelets. Twenty-seven patients
entered the study. All developed anti-HLA class I antibodies which
spontaneously disappeared. All sera were preserved at —40°C. In each
patient, we studied the serum sample (Abi +) which had the highest panel
reactivities and 1 negative current serum sample (Abi —). Panel reactivity
activities of Abl + and Abi — serum samples were tested by usual
lymphocytotoxicity assay with complement. Abi — serawere absorbed for
1 hour at 37°C, then 1 hour at 4°C on pooled platelets. Pooled platelets
were obtained from 50 donors. Ab2 occurrence in negative sera was
identified by the inhibition of Abi + sera lymphocytoxieity in presence of
Abi — sera. Three Abi + serum samples were incubated for 1 hour with an
equal volume of Abi — samples on one side, with Abi — serum absorbed
on pooled platelets on another side, and also with a negative control
subject (unsensitized against HLA antigens, blood group AB). These
incubations were followed by a lymphocytotoxicity assay which defined the
panel reactivity activity (PRA) for each Abl serum sample. We compared
Abl+ serum PRA after incubation with: (1) negative control serum; (2)
nonabsorbed Abi — serum; (3) Abi — absorbed serum. Statistical analysis
of PRA of Abi + sera after these 3 different incubations was performed by
the Friedman test. The 3 groups were then compared two by two using the
Wilcoxon test with the Bonferoni correction method. The mean PRA of
Abi + sera was 36.14 20.98% after incubation with negative control
serum, 33.35 25.37% with nonabsorbed Abi— serum, and 14.44
19.88% after incubation with absorbed Abi— serum. Friedman's test
within the 3 groups was significant (P < 0.0001). The comparison of
groups showed a significant decrease of PRA in AbI + serum by absorbed
Abi— serum:
Abl+/negative control 36.14 20.98%
NS
Ahl+/Abl— nonabsorbed 33.35 25.37%
P = 0.0001
Abl+/Abl— absorbed 14.44 19.88%
These data show that the absorption of Abi — sera on pooled platelets
increased the sensitivity of the detection of anti-HLA class I inhibiting
factors by lymphocytotoxicity assay. However, they have not definitely
proven that these inhibiting factors are anti-idiotypic antibodies. We are
presently studying the activity of F(ab')2 fragments of absorbed Abi —
sera on lymphocytotoxicity inhibition.
Randomized placebo-controlled trial of recombinant interleukin-2 in
chronic uremic patients, non-responders to hepatitis B vaccination. P.
Jungers, C. GeJfriaud-Ricouard, D. Dahmane, H. Fess4 J.P. Juquel, N.
Simon, A. Deschamps, and A. Meyrier, Department of Nephrology, Necker
Hospital, and Dialysis Units of Hôpital René-Dubos, Ponloise; Hôpital
Bichat, Pans; A URA, Paris; Centre Pasteur Valle,y-Radot, Paris; Clinique du
Parc Monceau, Paris; and Hôpital Avicenne, Bobigny, France. Despite
reinforced vaccination protocols, 20 to 40% of chronic uremic patients,
either dialyzed or not, exhibit no or poor antibody response to hepatitis B
vaccine, due to uremia-associated immune deficiency, including monocyte
dysfunction and defective biodisponibility of interleukin-2 (IL-2). Because
natural IL-2 at low dose combined with revaccination had been reported
to induce anti-HBs antibody production in previously non-responsive
dialysis patients, we prospectively evaluated the effect of a recombinant
human IL-2 (rh IL-2) preparation in previously non-responder chronic
uremic patients, in a placebo-controlled, randomized multicenter trial.
Included in the study were 52 patients (35 males, 27 females) including 28
(20 males) predialysis patients and 24 (15 males) patients on maintenance
hemodialysis, who all had produced no detectable antibody (26 cases) or
at a titer constantly lower than 10 mIU/ml (26 cases) following at least 4
vaccine injections. After informed consent, patients received 1 dose of the
pre-S2 containing recombinant Pasteur-Mérieux vaccine (GenHevac B®),
by subcutaneous route in the deltoid area, immediately followed by
injection by the same route and at the same site of 1 million U of rh IL-2
Roussel-Uclaf (27 patients), or of a placebo comprising the same vehicle
components devoid of imunostimulant properties (25 patients). Patients in
IL-2 and placebo groups did not differ with respect to age [60 11 vs. 57
15 years (mean su)I, sex ratio, body mass index, duration on
hemodialysis or degree of renal failure, and to the total number of
previous vaccine injections (7 6 vs. 6 3). Four weeks following
revaccination, the percentage of patients who developed seroconversion
(anti-HBs  2mIU/ml) did not significantly differ between the IL-2 group
(74%) and the placebo group (79%). Similarly, seroprotection (anti-HB5
10 mIU/ml) was observed in 56% of patients in the IL-2 group versus
67% in the placebo group, including a high response (50 mIU/ml) in
30% versus 44% of patients in the same groups, also non-significant
differences. In conclusion, our results do not confirm local injection of
IL-2, at least with the protocol we used, as an effective immunoadjuvant to
hepatitis B revaccination in previously unresponsive patients. However,
revaccination with a highly immunogenic vaccine by itself elicited sero-
protection in about 60% of the patients, thus confirming the interest of
repeated vaccine injections in uremic subjects until effective immune
protection is achieved.
Endothelin receptor antagonism: A new therapeutic approach in the
prevention of crush syndrome? H. Karam, P. Bruneval, J.-P. Clozel, B. -M
Loffler, J. Bariéty, and M. Clozel, Hoffmann-La Roche, Pharmaceutical
Division, Preclinical Research, Basel, Switzerland; and JNSERM U28,
J-lôpital Broussais, Paris, France. Crush syndrome is characterized by acute
renal failure due to massive myoglobin release. We tested the hypothesis
that endothelin-1, the most potent renal vasoconstrictor known, plays a
role in the renal toxicity of myoglobin. For this purpose, we induced
rhabdomyolysis (8 mI/kg i.m. of a 50% glycerol solution) in rats pretreated
or not pretreated with bosentan, a novel potent non-peptide endothelin
receptor antagonist. Glycerol dramatically decreased renal function, in-
creased proteinuria, and induced massive tubular necrosis. This effect was
associated with a 22% increase in plasma endothelin concentration.
Bosentan prevented the decrease in creatinine clearance induced by
glycerol (1.12 0.07mI/mm vs. 0.83 0.05 ml/min, P < 0.01), the increase
in proteinuria (65.4 mg/24 hr vs. 94.5 mg/24 hr, P < 0.001),and the tubular
necrosis as assessed by histopathological evaluation. Involvement of
endothelin was further suggested by the observation that myoglobin could
markedly increase endothelin-1 release by rat mesangial cells in culture
without affecting myoglobinuria. We conclude that endothelin is, at least
in part, responsible for the massive tubular necrosis observed in myoglo-
binuric nephropathy. Endothelin antagonists might be useful in the
prevention of the renal failure complicating crush injury.
Fibrinolytic therapy for renal vein thrombosis in adult nephrotic
syndrome. C. Mousson, N. El Khatib, Y. Tanter, f.M. Chalopin, J.P.
Cercueil, and G. Rifle, Departments of Nephrology and Radiology, University
Hospital, Dijon, France. The aims of renal vein thrombosis (RVT) therapy
are to prevent pulmonary embolism and also to protect renal function.
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The respective benefits of anticoagulant and fibrinolytic treatments re-
main unclear. This is particularly because of the lack of comparative
studies and also because the series in the literature is short. Patients and
methods: Eleven cases of RVT (5 men and 6 women) were retrospectively
studied. The mean age was 49 (range 15—72). Nine patients had nephrotic
syndrome due to membranous nephropathy, 1 membranoproliferative
glomerulonephritis, and 1 minimal change nephropathy. In 5 cases, RVT
and nephrotic syndrome were discovered simultaneously. Four patients
had renal failure (serum creatinine level between 185 and 705 mol/liter)
at presentation. Renal venography showed unilateral RVT in 5 cases and
bilateral RVT in 6 cases. RVT was associated with inferior vena cava
thrombosis in 6 patients. If there were no contraindications, patients with
bilateral RVT and/or unilateral RVT plus inferior vena cava thrombosis
initially received Urokinase, then anticoagulants (heparin and warfarin). If
there was a contraindication to thrombolytic therapy or unilateral RVT,
patients were treated by heparin only, then warfarin. In all patients at least
1 renal venogram or CT scan was performed during the follow-up.
Results: Two patients were treated by anticoagulants (AC) only because
of unilateral RVT, and 2 others because of a contraindication to throm-
bolytic therapy. Seven patients received fibrinolytics (F) for 36 hours to 6
days according to thrombosis lysis. In all cases, heparin was used during
1.5 to 4 months, then warfarin for 12 to 54 months (m = 27). The mean
follow-up after diagnosis was 76.2 months (range 17—211). At the end of
follow-up 10 patients were still alive and only 1 patient had died (group F),
on day 3, due to a large retroperitoneal hematoma (bilateral RVT +
inferior vena cava thrombosis, serum creatinine level = 734 jsmol/liter).
Only 1 pulmonary embolism occurred, in group AC, with a good outcome.
In group F, complete lysis of blood clots in the inferior vena cava occurred
between 3 to 12 days in 6 cases and remained incomplete in 1 case.
Complete repermeabilization of the 9 renal veins was observed between 3
and 24 months (m = 6.8). Two recurrences of thrombosis were identified
at 6 and 22 months. Serum creatinine levels returned to prethrombosis
values. In the AC group the repermeabilization was complete in 4 renal
veins between 8 days and 4.5 months (m = 1.9), and it was partial in I case
at 6 months. One renal vein thrombosis remained unchanged and 1
recurrence occurred at month 2. Serum creatinine levels returned to
normal in 1 case and decreased from 707 to 350 imo1/Iiter in another
patient. At the end of follow-up, nephrotic syndrome had disappeared in
6 cases, it was in partial remission in 3 cases and remained unchanged in
1 ease. Conclusion: Rapid repermeabilization of the inferior vena cava and
of some renal veins was observed with fibrinolytic therapy, without
increasing the risk of pulmonary embolism or bleeding.
Use of digoxin-specific antibody fragments in the treatment of digoxin
intoxication in hemodialysis patients. B. Page and F. Jacobs, Department of
Nephrology, Necker Hospital, Paris, France. Administration of digoxin
immune antibody fragments (Fab) is an established treatment of severe
digoxin intoxication. After intravenous injection, Fab fragments are
cleared rapidly from the circulation by glomerular filtration. A potential
problem involves patients with digoxin toxicity and renal failure. Failure to
clear the digoxin bound to Fab fragments from the circulation could result
in renewed digoxin toxicity upon metabolic degradation of the Fab
complex and release of bound digoxin. We describe 2 hemodialysis
patients with digoxin intoxication. Both developed symptoms of severe
digoxin intoxication treated with digoxin specific Fab fragments. In both
cases, administration of Fab fragments resulted in immediate reversal of
the clinical manifestations of digoxin toxicity. Both survived. There was no
evidence of digoxin toxicity after treatment by Fab fragments. Conclusion:
We suggest that administration of digoxin specific antibody fragments is
the therapy of choice of digoxin intoxication in renal failure and in
hemodialysis patients, and that no release of digoxin from Fab complex is
observed in such patients.
Seroma formation associated with PTFE vascular grafts used as
arteriovenous fistulae. B. Page and R. Maillet, Department of Nephrology,
Necker Hospital, Paris, France. Polytetrafluoroethylene (PTFE) grafts are
frequently used to create arteriovenous fistulae for hemodialysis, espe-
cially when superficial veins are no longer usable. Seroma formation after
PTFE graft has rarely been reported. We observed this complication,
termed "high porosity PTFE graft" or "seroma," in 3 cases. All had the
same 6 characteristics:
(1) The swelling (seroma) was localized near the arterial anastomosis.
(2) The seroma appeared in the first 2 postoperative weeks.
(3) The seroma persisted despite repeated drainage and surgery.
(4) Inspection of the graft surface during surgery revealed plasma
seeping through the graft wall.
(5) Infection of the graft due to staphylococcus was present in all 3
cases. This infection did not respond to adequate and prolonged
antibiotic therapy.
(6) In all three cases the graft could not be used for hemodialysis and
had to be totally excised.
Conclusion: Seroma is a rare complication of a PTFE graft used as an
arteriovenous flstula. Infection due to staphylococcus is occasionally
present. Successful treatment required total excision of the graft in our 3
patients.
Clotting of vascular access in dialysis patients with systemic lupus
erythematosus and anticardiolipin antibodies. B. Page and J. Zingraff
Department of Nephrology, Necker Hospital, Paris, France. Antiphospho-
lipid antibodies, namely lupus anticoagulant (LA) and anticardiolipin
antibodies (ACA), are a family of autoantibodies associated with throm-
bosis, spontaneous fetal loss, and thrombocytopenia. These antibodies
have been mainly demonstrated in the sera of patients with systemic lupus
elythematosus (SLE). In a small number of dialysis patients, vascular
access remains a problem of major concern because of repeated clotting of
the arteriovenous fistula. We report a series of three hemodialyzed
patients, all female, admitted for repair of obstructed AV fistula. All
patients have SLE, based on clinical history, SLE nephropathy, the criteria
of the American Rheumatism Association, and anti-DNA antibodies. The
search for ACA was significantly positive in these patients, ranging from
75 to 100 GPL units. IgG ACA were determined by ELISA. The result was
considered to be positive for values > 40 GPL units (2 so above the mean
of controls). LA was present in 2 patients. Clotting tests, including
determination of protein C, protein 5, and antithrombin III, were normal
in all 3 patients. Conclusions: (1) These dialysis patients with SLE, having
repeated clotting of vascular access and presence of ACA, may be
considered to be suffering from antiphospholipid syndrome; (2) The
presence of ACA should be sought systematically in dialysis patients with
SLE and clotting of AV fistula.
Recurrent clotting of arteriovenous fistula associated with coagulation
abnormalities in dialysis patients. B. Page and J. Zingraff Department of
Nephrology, Necker Hospital Pans France. In a small number of hemodi-
alysis patients, vascular access remains a problem of major concern
because of repeated clotting of the arteriovenous fistula. We report a
series of 30 hemodialysis patients, 16 females and 14 males, aged 25 to 78
years (mean 50), admitted for recurrent clotting of vascular access.
Patients underwent a mean of 9.4 thrombotic episodes (range 2—21) over
7.9 years (range 1—21). Three patients have systemic lupus erythematosus(SLE), based on clinical history, SLE nephropathy and criteria of the
American Rhumatism Association. Coagulation study included platelet
count, quick time, factor II, V, VII + X levels, kaolin cephalin time,
fibrinogen, antithrombin III, protein C, and total and free protein S. IgG
anticardiolopin antibodies (ACA) were determined by ELISA. The result
was considered to be positive for values > 40 GPL units (mean of 50
normal sera plus 2 SD). The results are given in the table:
Deficit in protein C N = 3
Deficit in protein S N = 2
ACA(-t) N=14 SLE(+)
SLE(—)
N=3
N=11
Normal results N = 11
Lupus anticoagulant was present in 2 SLE patients. Anti-vitamin K
treatment was prescribed in 12 patients, with no recurrence of clotting. We
conclude that in hemodialysis patients with repeated clotting of vascular
access, a deficiency of coagulation inhibitor and presence of ACA should
be routinely sought.
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Improvement of lipid profile in patients on polyamide membrane
hemodialysis. V. de Précigout, D. Higueret, N. Larroumet, C. Combe, A.
Pommereau, V. Blanchetier, and M. Aparicio, Hôpital Pellegrin Tnpode,
Bordeaux, France. The frequent abnormalities in lipid metabolism in
hemodialyzed patients increase cardiovascular morbidity and mortality
and are thought to be partially corrected by certain highly permeable
membranes, such as polysulfone or cellulose triacetate. We investigated
the influence of a polyamide membrane (polyfiux 130, Lab Gambro) after
4 months upon the course of lipid parameters in 6 patients aged 56.5 5.7
years, presenting hypertrglyceridemia> 2 mmollliter while on bicarbonate
dialysis with a cellulose membrane for 41.5 2.9 months. Anticoagulation
was not modified during the study. Plasma lipolytic activity was measured
immediately before a dialysis session after injection of 100 p1kg heparin.
The principal results were as follows:
TG Chol
HDL
CHOL
APO AL/B(mmol/liter)
0
4
3.94 117h
2.62 0.78"
6.07 0.4a
5.6 0.38a
0.80 0.17u 0.71 012b
0.89 0.18 0.99 011"
APO CII APO CIII LPL TGL
giliter UI/liter
0
4
62.8 15.9
49.8 14.7
204 501"
184 461"
6.7 2.3" 10.6 4.8
16.4 1.7" 13.0 5.7
P  0.05; bp  0.02. Abbreviations
HTGL, Hepatic triglyceride lipase.
are: LPL, Lipoprotein lipase;
Lipid parameters improved after 4 months of hemodialysis with a poly-
amide membrane. Serum triglyceride and cholesterol levels decreased and
HDL cholesterol rose significantly. VLDL and LDL levels were lower
(NS) while HDL levels increased (P < 0.01). APO B decreased signifi-
cantly while there was a nonsignificant rise in APO Al. Post-heparin
lipoprotein lipase activity improved (P < 0.02), associated with a decrease(P < 0.02) in APO CIII. The use of highly permeable polyamide
membranes results in a considerable improvement in lipid disturbances of
dialysis patients that involves triglyceride metabolism and cholesterol as
well. This seems to be at least partially attributable to a considerable rise
in lipoprotein lipase activity secondaly perhaps to a decrease in the
inhibitor APO CIII. The possibility of a circulatory inhibitor of LPL
removed by polyamide but not by cellulose membrane cannot be excluded.
Treatment of amyloidosis by the association of plasma exchange and
cytotoxic drugs: A pilot study. G. Rifle, C. Mousson, A. Bernard, E.
Justrabo, Y. Tanter, and K Charfeddine, Departments of Nephrology,
Biochemistry and Histology, University Hospital, Dijon, France. Melphalan
and prednisone therapy slightly improve AL amyloidosis prognosis in
patients with more than 1 organ involved, whereas plasma exchange seems
to have no beneficial effects in this disease. However, several theoretical
arguments suggest that the combination of these 2 therapies could be
interesting. Therefore, we• carried out a pilot study which associated
plasma exchange with cytotoxic drugs. Patients and methods: Seven
patients entered the ttudy: 5 of them had AL amyloidosis and 2 women
had AA amyloidosis secondary to rheumatoid arthritis. Four out of 5 AL
amyloidosis were associated with monoclonal gammapathies (2 IgGA and
2A) without multiple myeloma. Mean age was 57 (range 36—71). All
patients had more than 2 (biopsy proven) amyloid infiltrated organs.
Moreover, 2 life-threatening organs (heart, liver or kidneys) had to be
involved to enter the study. Treatment associated plasma exchanges (60
mi/kg body wt per session) were done 3 times a week for 1 month. It was
progressively tapered to once a week and cytotoxic drugs (cyclophospha-
mide, melphalan, prednisone) were given every 4 or 6 weeks. This
treatment lasted for 24 months (maximum). Serum amyloid A and P
proteins were regularly measured by quantitative radial immunodiffusion
assay in 4 patients. Results: In AL amyloidosis, mean patient survival was
58 months, and 3 out of 5 patients survived more than 5 years. Four
patients died, respectively at 60 (acute leukemia), 96 (amyloid myocardi-
opathy), 13 (amyloid myocardiopathy) and 14 (cachexia) months. Ne-
phrotic syndrome decreased in 2 out of 3 patients, but renal failure
appeared or worsened in 2 others. In 1 patient, still alive 108 months
after the diagnosis, amyloid deposits disappeared in the liver and
decreased in the kidneys. In 2 out of 4 cases, monoclonal gammapathies
disappeared. Two patients with AA amyloidosis were still alive after 34
and 15 months of treatment. Serum amyloid A protein levels were
correlated with C-reactive protein levels, but not with the therapy.
Initial serum protein P amyloid levels were not different from those of
control subjects. Serum protein P levels decreased with the combina-
tion of plasma exchange + cytotoxic agents, but not with cytotoxic
agents alone in a given patient. Conclusion: These preliminary data, in
a small, voluntarily limited number of patients, showed a much longer
survival rate than expected, even with cytotoxic drugs alone. Indeed,
"primitive" AL amyloidosis patients' survival rates were inferior than
20% at 4 years with prednisone-melphalan therapy, particularly when
there was a nephrotic syndrome. Mean survival rate was less than 12
months in patients with amyloid myocardiopathy. The disappearance of
amyloid deposits is also very rare. Except for the ease of late acute
leukemia, side effects were mild. So, the possibility of a randomized
study should be considered.
